<DOC>
	<DOCNO>NCT00040885</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , docetaxel , work different way stop tumor cell divide stop grow die . Infliximab may improve cancer-related weight loss , lack appetite , fatigue . It yet know whether docetaxel effective without infliximab prevent weight loss fatigue patient advance cancer . ( Infliximab treatment discontinue effective 10/05/05 ) PURPOSE : Randomized phase III trial determine effectiveness docetaxel without infliximab prevent weight loss , loss appetite , fatigue patient unresectable non-small cell lung cancer . ( Infliximab treatment discontinue effective 10/05/05 )</brief_summary>
	<brief_title>Docetaxel With Without Infliximab Treating Weight Loss , Loss Appetite , Fatigue Patients With Unresectable Non-Small Cell Lung Cancer ( Infliximab Treatment Discontinued Effective 10/05/05 )</brief_title>
	<detailed_description>OBJECTIVES : - Compare improvement stabilization weight elderly poor performance status patient unresectable non-small cell lung cancer treat docetaxel without infliximab ( infliximab treatment discontinue effective 10/05/05 ) . - Compare appetite functional status patient treat regimen . - Compare toxicity regimens patient . - Compare augmentation maintenance lean tissue patient treat regimen . - Compare response rate time disease progression patient treat regimen . - Compare survival patient treat regimen . - Determine whether tumor necrosis factor-alpha polymorphism -308 -238 region predict cancer patient experience loss appetite weight patient might potentially benefit infliximab ( infliximab treatment discontinue effective 10/05/05 ) . OUTLINE : This randomize , double-blind , placebo-controlled , multicenter study . Patients stratify accord weight loss within past 6 month ( 0 % vs 0 % le 5 % v least 5 % ) , number prior chemotherapy regimen ( 0 vs 1 v 1 ) , gender , GBU prognostic index ( good v bad vs unsure ) . - Part A ( non-randomized , single-center portion study ) : Five patient receive infliximab IV ( infliximab treatment discontinue effective 10/05/05 ) 2 hour weekly week 1 , 3 , 5 first course weekly week 1 5 subsequent course docetaxel IV 1 hour ( immediately completion infliximab infusion [ infliximab treatment discontinue effective 10/05/05 ] ) weekly week 1-6 course . Treatment repeat every 8 week 2-3 course absence disease progression unacceptable toxicity . If none 5 patient experience grade 4 5 toxicity directly attributable infliximab ( infliximab treatment discontinue effective 10/05/05 ) , additional patient accrue part B study . - Part B ( randomize , multicenter portion study ) : Patients randomize 1 2 treatment arm . - Arm I ( infliximab treatment discontinue effective 10/05/05 ) : Patients receive infliximab docetaxel part A . - Arm II : Patients receive docetaxel part A placebo IV 2 hour accord infliximab schedule part A ( infliximab treatment discontinue effective 10/05/05 ) . Treatment arm repeat part A . Quality life , fatigue , appetite/anorexia , cachexia , weight assess baseline , weekly week 1-8 , monthly remainder study treatment . Patients follow every 6 month 5 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Anorexia</mesh_term>
	<mesh_term>Cachexia</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm unresectable nonsmall cell lung cancer consider incurable therapy Chemotherapy naive previously treat disease Meets one follow criterion : Age 65 ECOG performance status 02 Under age 65 ECOG performance status 2 No symptomatic know untreated brain metastasis PATIENT CHARACTERISTICS : Age : See Disease Characteristics Adult Performance status : See Disease Characteristics ECOG 02 Life expectancy : At least 3 month Hematopoietic : Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic : Bilirubin normal AST and/or ALT ≤ 2.5 time upper limit normal ( ULN ) alkaline phosphatase le ULN OR Alkaline phosphatase ≤ 4 time ULN ALT less ULN No ascites Renal : Creatinine ≤ 1.5 time ULN Cardiovascular : No prior concurrent congestive heart failure Pulmonary : No prior tuberculosis positive purify protein derivative skin test ( tuberculin test ) Other : No prior anaphylactic reaction taxane No known mechanical obstruction alimentary tract , malabsorption , intractable vomiting ( 5 episode per week ) No infection chronic debilitate illness would increase risk chemotherapy administration No grade 2 great peripheral neuropathy etiology No edema No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer Alert mentally competent Able complete questionnaire alone assistance Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics No prior docetaxel metastatic nonsmall cell lung cancer Endocrine therapy : At least 1 month since prior adrenal steroid , androgen , progestational agent , appetite stimulant No concurrent adrenal steroid , androgen , progestational agent , appetite stimulant unless need ( e.g. , steroid CNS metastasis ) Concurrent inhale , topical , optical steroid allow Concurrent shortterm dexamethasone around day chemotherapy administration allow protection anaphylaxis emesis Radiotherapy : More 3 week since prior radiotherapy No prior radiotherapy 25 % bone marrow Surgery : More 3 week since prior major surgery Other : More 3 week since prior antineoplastic therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>fatigue</keyword>
	<keyword>anorexia</keyword>
	<keyword>cachexia</keyword>
</DOC>